April 26, 2012 ·
Leave a comment
April 26, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of an inter-disciplinary infectious disease engagement with a top 10 global biopharmaceutical company.
The biopharmaceutical company, part of a select group of global leaders in drug development for the treatment of infectious diseases, approached Thought Leader Select for support with its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s emerging pipeline in treating conditions like HIV and Hepatitis-C, Thought Leader Select will deploy its in-house research group for a multi-disciplinary assessment of the key opinion leader community in infectious diseases.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following areas:
For the first wave of the assessment, the Thought Leader Select research group will identify 50 physicians appropriate for compliant engagement in support of drug development for infectious diseases, across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought leaders, ... read more »
April 18, 2012 ·
Leave a comment
April 18, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a urology engagement with a top 20 global pharmaceutical company.
The pharmaceutical company, a global leader in drug development for urological conditions, approached Thought Leader Select for support with its existing portfolio of medicines, as well as new drugs in its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s existing portfolio as well as its emerging pipeline, Thought Leader Select will deploy its in-house research group for a two-part assessment of the key opinion leader community in urology.
For the first wave of the assessment, the Thought Leader Select research group will validate the skills and experience of the urology specialists that currently comprise the company’s KOL roster. In addition, Thought Leader Select will identify new physicians appropriate for the panel, bringing the total roster to 40 thought leaders across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as ... read more »
April 12, 2012 ·
Leave a comment
New press release out today from the offices of Thought Leader Select:
April 12, 2012 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina-based consulting firm supporting the healthcare industry, is pleased to announce the hiring of Jason Bell as its newest sales executive for the American market.
Bell comes to Thought Leader Select with a solid track record of experience within the biopharmaceutical industry, working as a field hospital representative in support of critical new drug launches in multiple therapeutic areas and disease states, for companies including Allergan, Capellon Pharmaceuticals, and Auriga Pharmaceuticals. In addition to his in-the-field experience and perspective on collaborating with key opinion leaders in medicine to promote effective new treatments, Bell also brings experience gleaned from his time at Clinsys Alterna, a contract research organization (CRO). In his business development role at Clinsys Alterna, Jason consulted with biopharmaceutical industry executives to deliver customized solutions in support of phase I-IV clinical trials.
Jason Bell is a 1997 graduate of California University of Pennsylvania, with a degree in psychology.
“I’m already enjoying my work, speaking with clients and prospective clients about their needs for medical marketing and medical science outreach to health care professionals,” stated Bell. “This company is a great match for my experience and the skills I developed in pharma, CROs, and talent management organizations serving life science ... read more »
April 10, 2012 ·
Leave a comment
Industry Insights from Kristen Smithwick
Last week proved to be another interesting week for the developing Sunshine Act. Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) sent a pivotal memo to Acting CMS Administrator Marilyn Tavenner. The senators urged the agency to publish a final rule no later than June 2012 and to respond to several questions related to implementation.
Senators Grassley and Kohl want the agency to begin gathering transparency data this year, and they’re not willing to give CMS any wiggle room for delays. To meet the senators’ timeline, CMS will need to address comments and recommendations from numerous interested parties, especially the Pharmaceutical Research and Manufacturers of America (PhRMA), the Advanced Medical Technology Association (AdvaMed), and the Biotechnology Industry Organization (BIO). We covered a number of areas questioned in Part 1 of this blog. In this post, we’ll mention just a few additional areas of concern.
Definition of Applicable Manufacturer and Separate vs. Consolidated Reporting – Questions and concerns abound when it comes to defining applicable manufacturers, especially as the definition impacts requirements for separate vs. consolidated reporting for entities with common ownership. The challenge for CMS will be to ensure the definitions of applicable manufacturers and common ownership are broad enough to meet the public’s demand for transparency, while being specific enough to protect the ... read more »